Tu banner alternativo

Cyclorphan

In today's world, Cyclorphan has become a topic of great relevance and interest to a wide sector of society. Whether due to its impact on the economy, politics, science or people's daily lives, Cyclorphan has sparked great debate and analysis in various areas. In this article we will explore the different facets and perspectives related to Cyclorphan, as well as its influence on the world today. Through various sources and approaches, we will try to shed light on this topic and offer a more complete and profound vision of its importance and consequences.

Tu banner alternativo
Cyclorphan
Identifiers
  • (−)-3-Hydroxy-N-cyclopropylmethylmorphinan
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.021.825 Edit this at Wikidata
Chemical and physical data
FormulaC20H27NO
Molar mass297.442 g·mol−1
3D model (JSmol)
Density1.19 g/cm3
Melting point188 °C (370 °F)
Boiling point458.4 °C (857.1 °F)
  • Oc1ccc4c(c1)25((N(CC2)CC3CC3)C4)CCCC5

Cyclorphan is an opioid analgesic of the morphinan family that was never marketed.[1] It acts as a μ-opioid receptor (MOR) weak partial agonist or antagonist, κ-opioid receptor (KOR) full agonist, and, to a much lesser extent, δ-opioid receptor (DOR) agonist (75-fold lower affinity relative to the KOR).[2][3] The drug was first synthesized in 1964 by scientists at Research Corporation.[4][5]: 232  In clinical trials, it had relatively long duration, good absorption, and provided strong pain relief but produced psychotomimetic effects via KOR activation, so its development was not continued.[1][5]: 232, 237 

See also

References

  1. ^ a b Maxwell Gordon (2 December 2012). Psychopharmacological Agents. Elsevier Science. pp. 19–. ISBN 978-0-323-15963-0.
  2. ^ Linda P. Dwoskin (29 January 2014). Emerging Targets & Therapeutics in the Treatment of Psychostimulant Abuse. Elsevier Science. pp. 403–. ISBN 978-0-12-420177-4.
  3. ^ Aldrich JV, Vigil-Cruz SC (2003). "Narcotic Analgesics". Burger's Medicinal Chemistry and Drug Discovery (7th ed.). pp. 331–482. doi:10.1002/0471266949.bmc100. ISBN 9780471266945.
  4. ^ US Patent 3,285,922
  5. ^ a b Varghese V & Hudlicky T. A Short History of the Discovery and Development of Naltrexone and Other Morphine Derivatives. Chapter 6 in Natural Products in Medicinal Chemistry, Volume 60 of Methods and Principles in Medicinal Chemistry. Ed. Stephen Hanessian. John Wiley & Sons, 2013. ISBN 9783527676552